Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2022; 14(11): 2157-2169
Published online Nov 15, 2022. doi: 10.4251/wjgo.v14.i11.2157
Published online Nov 15, 2022. doi: 10.4251/wjgo.v14.i11.2157
KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6
Wei Mi, Zhi Zheng, Hai-Qiao Zhang, Jie Yin, Jun Zhang, Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Jiong-Di Lu, Yi-Xuan Ding, Feng Cao, Fei Li, Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
Shu-Quan Duan, Department of Digestive Minimally Invasive Surgery, The Second Affiliated Hospital of Baotou Medical College, Baotou 014030, Inner Mongolia Autonomous Region, China
Jie Zhang, Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Author contributions: Mi W, Zheng Z, Lu JD, Duan SQ, Zhang J and Zhang HQ all contributed equally to this work; Mi W, Zheng Z, Lu JD and Duan SQ designed the study; Zhang HQ, Yin J and Zhang J performed the experiments; Zheng Z and Lu JD wrote the manuscript; Ding YX and Cao F performed statistical analysis; Li F and Zhang J revised the manuscript; All authors read and approved the final manuscript.
Institutional review board statement: The research was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University (No. 2018-P2-015-02). The principles outlined in the Declaration of Helsinki were adhered to throughout the course of this research project (as revised in 2013).
Institutional animal care and use committee statement: Every experiment that included animals was carried out in compliance with the Principles on the Protection of Experimental Animals that are outlined by the Beijing Friendship Hospital.
Conflict-of-interest statement: All authors report having no relevant conflict of interest for this article.
Data sharing statement: Data are available from the corresponding authors upon request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun Zhang, MD, PhD, Chief Doctor, General Surgery Department, Beijing Friendship Hospital, Capital Medical University, No. 95 Yongan Road, Xi-Cheng District, Beijing 100050, China. zhangjun5986@ccmu.edu.cn
Received: July 15, 2022
Peer-review started: July 15, 2022
First decision: July 28, 2022
Revised: September 10, 2022
Accepted: October 18, 2022
Article in press: October 18, 2022
Published online: November 15, 2022
Peer-review started: July 15, 2022
First decision: July 28, 2022
Revised: September 10, 2022
Accepted: October 18, 2022
Article in press: October 18, 2022
Published online: November 15, 2022
Core Tip
Core Tip: Our study provided the evidence that KLF16 acted as an oncogene in pancreatic adenocarcinoma (PAAD). We also identified that SMAD6 served as the downstream substrate of KLF16 and this signaling cascade has never been reported. This mechanism indicated a novel insight into the pathological events during the development of PAAD.